Obsidian Therapeutics, Inc. (OBX) Stock Analysis
Healthcare · Biotechnology
DATA_ISSUE. No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run.
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced... Read more
DATA_ISSUE. No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run. Score 4.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-08-17Recent Developments — Obsidian Therapeutics, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Friday's After-Market Session — benzinga Aug 14, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga Aug 13, 2026 neutral
Generated 2026-08-17T15:12:20Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
0Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
DATA_ISSUE. No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run. Target $0.00 (-100.0%), stop $0.00 (−0.0%), A.R:R 0.0:1. Score 4.9/10, moderate confidence.
Price unavailable this run — no trade setup.
Obsidian Therapeutics, Inc. trades at a P/E of N/A (forward -8.3). TrendMatrix value score: 5.0/10. Verdict: DATA_ISSUE.
What does Obsidian Therapeutics, Inc. do?Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene...
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.